HeartFlow, Inc. (HTFL)
| Market Cap | 4.34B +54.8% |
| Revenue (ttm) | 212.07M +42.8% |
| Net Income | -118.37M |
| EPS | -1.54 |
| Shares Out | 86.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,273,163 |
| Open | 46.11 |
| Previous Close | 45.49 |
| Day's Range | 45.60 - 50.23 |
| 52-Week Range | 20.13 - 51.78 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 44.78 (-10.22%) |
| Earnings Date | Aug 13, 2026 |
About HTFL
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient’s heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart’s arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heart... [Read more]
Financial Performance
In 2025, HeartFlow's revenue was $176.03 million, an increase of 39.92% compared to the previous year's $125.81 million. Losses were -$116.79 million, 21.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for HTFL stock is "Buy." The 12-month stock price target is $44.78, which is a decrease of -10.22% from the latest price.
News
HeartFlow Transcript: Wells Fargo 21st Annual Healthcare Conference
AI-driven coronary artery disease diagnostics are accelerating growth, with Plaque Analysis adoption and revenue surging, supported by robust clinical data and expanding payer coverage. Strategic RCTs target a $6B asymptomatic market, aiming for $11B TAM by 2030 and profitability by mid-2028.
Heartflow initiated with a Neutral at UBS
UBS initiated coverage of Heartflow (HTFL) with a Neutral rating and $55 price target The firm initiated and resumed 25 life science and diagnostics tools companies. UBS views life science…
Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, suppo...
Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference
SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that...
Heartflow price target raised to $40 from $35 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on Heartflow (HTFL) to $40 from $35 and keeps an Equal Weight rating on the shares.
Heartflow reports Q2 EPS (7c), consensus (13c)
Reports Q2 revenue $64.1M, consensus $56.64M. “The second quarter reflects the growing strength of Heartflow’s (HTFL) category leadership and unique AI technology platform for identifying, diagnosing,...
Heartflow increases FY26 revenue view to $246M-$250M from $228M-$232M
Consensus $230.08M
Heartflow price target raised to $45 from $34 at Baird
Baird raised the firm’s price target on Heartflow (HTFL) to $45 from $34 and keeps a Neutral rating on the shares. The firm updated its model following blowout beat and…
Heartflow price target raised to $45 from $40 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Heartflow (HTFL) to $45 from $40 and keeps a Buy rating on the shares after the company’s 2026 revenue guidance,…
Heartflow price target raised to $45 from $35 at JPMorgan
JPMorgan raised the firm’s price target on Heartflow (HTFL) to $45 from $35 and keeps an Overweight rating on the shares. The company reported a big Q2 beat and even…
Heartflow price target raised to $45 from $38 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Heartflow (HTFL) to $45 from $38 and keeps an Overweight rating on the shares. The firm notes the company…
Heartflow price target raised to $45 from $37 at Canaccord
Canaccord analyst William Plovanic raised the firm’s price target on Heartflow (HTFL) to $45 from $37 and keeps a Buy rating on the shares. The firm said Heartflow delivered the…
Heartflow price target raised to $40 from $35 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Heartflow (HTFL) to $40 from $35 and keeps an Equal Weight rating on the shares. The firm updated its model for Q2…
HeartFlow Earnings Call Transcript: Q2 2026
Q2 revenue grew 48% year-over-year to $64.1 million, driven by strong plaque and FF-RCT adoption, with gross margin expanding to 83.3%. Full-year guidance was raised, reflecting continued commercial momentum, innovation, and robust clinical evidence.
HeartFlow Earnings release: Q2 2026
HeartFlow released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
HeartFlow Quarterly report: Q2 2026
HeartFlow has published its Q2 2026 quarterly earnings report on August 13, 2026.
Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results ...
Heartflow initiated with an Outperform at Baird
Baird analyst David Rescott initiated coverage of Heartflow (HTFL) with an Outperform rating and $34 price target The company is playing a “key role in driving a paradigm shift” away…
Heartflow to Report Second Quarter 2026 Financial Results on August 13, 2026
SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial re...
New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management
Heartflow Plaque Staging TM , the only staging tool based on total plaque volume * , is now included with every Heartflow Plaque Analysis Data from over 36,000 patients validate the accuracy, reproduc...
Heartflow initiated with a Buy at Freedom Capital
Freedom Capital initiated coverage of Heartflow (HTFL) with a Buy rating and $37 price target Healthcare AI is one of the fastest-growing technology segments, says the analyst, who found that…
